New publication in Molecular Cancer

Berlin, Germany, 6-23-2023 Large quantities of the protein IGF2BP2 not only make bowel cancer grow faster, but they also make it resistant to common forms of chemotherapy. This discovery was made by a research team led by Martin Luther University Halle-Wittenberg (MLU) and Saarland University with the collaboration of CELLphenomics. For its new study, published […]

Bionity.com

Bionity.com is the leading portal for Life Sciences and Pharma in the key markets of Europe, the USA, and Asia with over 2.6 million users. The website reported about the new partnership between CELLphenomics and Kyan Therapeutics and wrote, that the „two unique technologies will allow reliable conclusions about the treatability of the tumor and […]

Precision Medicine Online

The website precisionmedicineonline.com, published by Genome Web, reports on the new partnership between Indivumed and Cellphenomics, and discusses how both companies are collaborating on cancer drug research. The partnership promises significant advancement in cancer research, as it allows both companies to combine their expertise and resources to explore innovative approaches to cancer drug development

Transkript.de

Transkript.de reports about the new partnership of CELLphenomics and KYAN Therapeutics. By combining KYAN’s technology platform, Optim.AI™ – which utilizes artificial intelligence to predict the effects of drug combinations and CELLphenomics‘ proprietary PD3D® technology, this partnership aims to offer an efficient approach to expedite drug development process in the biopharmaceutical industry.

Kyan Therapeutics and CELLphenomics announce new partnership

Berlin/Singapore 4-14-2023  CELLphenomics and KYAN Therapeutics announced their new partnership today. By combining KYAN’s technology platform, Optim.AI™ – which utilizes artificial intelligence to predict the effects of drug combinations and CELLphenomics‘ proprietary PD3D® technology, this partnership aims to offer an efficient approach to expedite drug development process in the biopharmaceutical industry. The combination of these […]

Christian Regenbrecht

Dr. Christian Regenbrecht is co-founder and CEO of CELLphenomics.Prior to founding CELLphenomics, Christian was principal investigator at the Institute of Pathology, Charité – Universitätsmedizin Berlin and was responsible for the establishment of complex cell culture models in several publicly funded projects, including IMI’s Oncotrack and BMBF’s TREAT20. In this role, Christian acquired external funding from […]

Quirin Graf Adelmann

Quirin Graf Adelmann was born near Munich and grew up bilingually in France and Germany. After studying law at Humboldt University in Berlin, he worked as an employed managing director in the automotive and real estate sectors before becoming an independent entrepreneur in 2010.Quirin is active in the fields of culture, health, FinTech, GovTech, BioTech, […]

Christoph Reinhard

Dr. Christoph Reinhard has spend his whole career in oncology drug development in biotechnology and pharma companies with a special focus on target identification and translational research. Special emphasis lies on technologies to identify and utilize biomarkers for drug efficacy and tumor prognosis. Christoph strived to complement the company specific research with engagement in large […]

Lena Wedeken

Dr. Lena Wedeken studied human biology at the Philipps-University Marburg, Germany and obtained her PhD in molecular biology/biochemistry from the Westfälische Wilhelms-University Münster, Germany in 2011. During her postdoctoral fellowship in stem cell biology at the Beckman Research Institute of City of Hope in Duarte, CA, USA, she became an expert in the derivation and […]

Indivumed and CELLphenomics announce their new partnership

Berlin/Hamburg, Germany, 9-7-2022 The Indivumed GmbH and the CELLphenomics GmbH today announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed’s AI-driven oncology analytics with CELLphenomics’ expertise in creating organoid models to identify therapeutically relevant targets and validate these targets in-vitro. The partnership […]